FOLH1 and neoplasm: [61Cu]Cu-NODAGA-PSMA-I&T had higher tumor-to-nontumor ratios than [61Cu]Cu-DOTAGA-PSMA-I&T (Table 3), with the exception of the tumor-to-kidney ratio at 4 h after injection.